Cresco Labs Q2 Revenue Hits $173M, Adjusted EBITDA $40M; CFO Steps Down Amid Federal Rescheduling Tailwind
CRLBF is trading near its 52-week low of $0.588 (12% above the low).
Summary
Cresco Labs posted Q2 2026 revenue of $173 million and Adjusted EBITDA of $40 million, both up sequentially, and swung to a net profit aided by a tax benefit from federal rescheduling of medical cannabis. CFO Sharon Schuler is stepping down, and the company closed a new $50 million credit facility.
Key Events · Earnings and Guidance · CRLBF
-
Q2 Revenue and Profit Surge
Revenue reached $173 million, up 15% sequentially, with net income of $15 million compared to a $13.9 million loss in Q2 2025. Adjusted EBITDA rose 20% sequentially to $40 million.
-
Federal Rescheduling Tax Windfall
The DEA's April 22, 2026 order moving state-licensed medical cannabis to Schedule III eliminated IRC Section 280E for medical operations, resulting in a $26.7 million net tax benefit in Q2 and fundamentally improving future after-tax earnings.
-
CFO Departure and Interim Appointment
CFO Sharon Schuler is stepping down; Senior VP and Corporate Controller Mark Stortz will serve as interim CFO while the company searches for a permanent replacement with strategic priorities in mind.
-
New $50M Revolving Credit Facility
On June 5, 2026, the company closed a $50 million revolving credit facility maturing in 2030 at 7.99% interest, providing additional liquidity for growth initiatives and general corporate purposes.
Analysis · CRLBF · Life Sciences
A strong second quarter saw revenue climb 15% sequentially to $173 million and Adjusted EBITDA jump 20% to $40 million, fueled by the consolidation of Pennsylvania dispensaries and accelerating adult-use sales in Ohio. The bottom line swung dramatically to a $15 million profit from a $13.9 million loss a year ago, largely thanks to a $26.7 million tax benefit triggered by the DEA's rescheduling of medical cannabis to Schedule III—a move that eliminates the punitive 280E tax burden on medical operations. While the departure of the CFO introduces near-term leadership uncertainty, a search for a permanent replacement is already underway. The new $50 million revolving credit facility and the rescheduling tailwind together strengthen the balance sheet and open a path to U.S. exchange listings, though adult-use cannabis remains federally illegal and subject to 280E.
At the time of this filing, CRLBF was trading at $0.66 on OTC in the Life Sciences sector, with a market capitalization of approximately $303.5M. The 52-week trading range was $0.59 to $2.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.